Skip to main content
. Author manuscript; available in PMC: 2013 Oct 1.
Published in final edited form as: Pharmacogenomics J. 2012 Jan 10;13(2):173–180. doi: 10.1038/tpj.2011.61

Figure 1.

Figure 1

Figure 1

Figure 1a: RR to FOLFOX/XELOX and bevacizumab

≤7.76: low intratumoral CD133 gene expression levels

>7.76: high intratumoral CD133 gene expression level

Figure 1b: PFS for the combination of single nucleotide polymorphisms rs3130 and rs2086455. Patients with the favorable combination of alleles (either homozygous for C/C in both polymorphisms or the combination of C/T in rs2086455 with either C/T or T/T in rs3130) showed a significantly increased PFS, compared to a decreased PFS for patients with C/C in one polymorphism and C/T or T/T in the other polymorphism (unfavorable alleles).